Search

Your search keyword '"Gent, Dik C."' showing total 416 results

Search Constraints

Start Over You searched for: Author "Gent, Dik C." Remove constraint Author: "Gent, Dik C."
416 results on '"Gent, Dik C."'

Search Results

2. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests

Catalog

Books, media, physical & digital resources

3. Development of an Ex Vivo Functional Assay for Prediction of Irradiation Related Toxicity in Healthy Oral Mucosa Tissue

4. Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient

7. The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells

9. Supplementary Data from A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture

10. Data from A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture

11. Establishing a Microfluidic Tumor Slice Culture Platform to Study Drug Response

12. Ex Vivo Functional Assay for Evaluating Treatment Response in Tumor Tissue of Head and Neck Squamous Cell Carcinoma

13. XLF deficiency results in reduced N-nucleotide addition during V(D)J recombination

14. Supplemental legend from Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects

15. Figure S3 from Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects

16. Table S1, Table S2, Table S3 from Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects

17. Data from A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair

18. Supplementary Data from A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair

20. Ex Vivo Functional Assay for Evaluating Treatment Response in Tumor Tissue of Head and Neck Squamous Cell Carcinoma

24. Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes

25. tumors may acquire therapy resistance through expression of RING-less BRCA1

28. Rapid recruitment of p53 to DNA damage sites directs DNA repair choice and integrity

29. The COMPLETE trial:HolistiC early respOnse assessMent for oroPharyngeaL cancEr paTiEnts; Protocol for an observational study

30. Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment

31. Functional Ex Vivo Tissue-Based Chemotherapy Sensitivity Testing for Breast Cancer

32. A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture

33. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests

34. REV7 counteracts DNA double-strand break resection and affects PARP inhibition

35. Abstract 805: RECAP (REpair CAPacity) identifies a subset of breast cancers unable to form RAD51 foci which are undetected by DNA-based BRCAness tests

36. The COMPLETE trial: HolistiC early respOnse assessMent for oroPharyngeaL cancEr paTiEnts; Protocol for an observational study

37. Initiation of V(D)J Recombination in a Cell-Free System by RAG1 and RAG2 Proteins

40. Rapid recruitment of p53 to DNA damage sites directs DNA repair choice and integrity

43. A novel radiosensitive SCID patient with a pronounced G 2/M sensitivity

44. A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair

45. A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture

50. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy